The efficacy of intralesional triamcinolone acetonide (20mg/ml) in the treatment of keloid

Authors

  • Adit M. Garg Department of DVL, Era’s Lucknow Medical College and Hospital, Lucknow, Utter Pradesh, India
  • Yogesh M. Shah Department of DVL, Era’s Lucknow Medical College and Hospital, Lucknow, Utter Pradesh, India
  • Alok Garg Consultant Plastic Surgeon, Alok Hospital, Talwandi, Kota, Rajasthan, India
  • Shazia Zaidi Department of DVL, Era’s Lucknow Medical College and Hospital, Lucknow, Utter Pradesh, India
  • Kshitij Saxena Department of DVL, Era’s Lucknow Medical College and Hospital, Lucknow, Utter Pradesh, India
  • Khushboo Gupta Department of DVL, Era’s Lucknow Medical College and Hospital, Lucknow, Utter Pradesh, India
  • Ramya B. G. Department of DVL, Era’s Lucknow Medical College and Hospital, Lucknow, Utter Pradesh, India

DOI:

https://doi.org/10.18203/2349-2902.isj20180497

Keywords:

Adverse effects, Efficacy, Keloid, Triamcinolone (20mg/ml), Vancouver scar scale

Abstract

Background: Management of keloid is difficult as well as challenging. Intralesional triamcinolone acetonide (TAC) injections have remained a gold standard in non-surgical management of keloid. TAC is generally used in the concentration of 40mg/ml, which causes adverse effects such as local dermal atrophy and hypopigmentation. Aim was to study efficacy and adverse effects of TAC in treatment of keloid, in a lesser concentration of 20mg/ml.

Methods: An open label study was conducted from November 2015 to May 2017 on 25 subjects of either gender, in the age group 11-55 years, at a medical college hospital. Intralesional injection TAC 20 was administered in the keloid at an interval of 3 weeks, for a total of 6 sessions, over a period of 18 weeks. Vancouver scar scale (VSS) was used to assess the improvement and SPSS 21 for statistical analysis.

Results: Mean age of keloid subjects was 30.72 years and median duration of keloid was 8 months. The mean VSS score before treatment was 8.36 which reduced to 3.20 after treatment. Mean percentage change in VSS score was 62.79%, which was very highly significant (p <0.001). Physician’s assessment was ‘Very Good’ in 52.0% and ‘Excellent’ in 5 (20%). Adverse effect of atrophy was seen in 3 (12%), hypopigmentation in 11 (44%) and telangiectasia in 4 (16%).

Conclusions: Intralesional injection triamcinolone acetonide 20mg/ml gives very good to excellent improvement in the majority of patients of keloid. Local adverse effects seen were hypopigmentation, atrophy and telengiectasia.

References

Lee SS, Yosipovitch G, Chan YH, Goh CL. Pruritus, pain, and small nerve fiber function in keloids: a controlled study. J Am Acad Dermatol. 2004;51:1002-6.

Burrows NP, Lovell CR. Disorders of Connective Tissue. In: Burns T, Rook A. Rooks textbook of dermatology. 8th Ed. Oxford: Wiley-Blackwell; 2010:45.54-45,56.

Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol. 2007;25:26-32.

Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg. 2008;206:719-30.

Cruz NI, Korchin L. Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg. 1994;33:401-5.

Boyadjiev C, Popchristova E, Mazgalova J. Histomorphologic changes in keloids treated with Kenacort. J Trauma. 1995;38:299-302.

Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560-71.

Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Molecular Medicine. 2011;17(1-2):113-25.

Tredget EE, Nedelec B, Scott PG, Ghahary A. Hypertrophic scars, keloids, and contractures: the cellular and molecular basis for therapy. Surg Clin North Am. 1997;77:701-30.

Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol. 2008;47(2):183-6.

Nedelec B, Shankowsky HA, Tredget EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil. 2000;21:205-12.

Li-Tsang CWP, Lau JCM, Liu SKY. Validation of an objective scar pigmentation measurement by using a spectrocolorimeter. Burns. 2003;29:779-84.

Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. J Burn Care Rehabil. 1995;16:535-8.

Ogawa R, Chin MS. Animal models of keloids and hypertrophic scars. J Burn Care Res. 2008;29:1016-7.

Shanthi FM, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian JDVL. 2008;74(4):343-8.

Carvalhaes SM, Petroianu A, Ferreira MAT, Barros VMD, Lopes RV. Assessment of the treatment of earlobe keloids with triamcinolone injections, surgical resection, and local pressure. Revista do Colégio Brasileiro de Cirurgiões. 2015;42(1):9-13.

Gupta S, Sharma V. Standard guidelines of care: Keloids and hypertrophic scars. Indian JDVL. 2011;77(1):94.

Wong TS, Li JZH, Chen S, Chan JYW, Gao W. The Efficacy of Triamcinolone Acetonide in Keloid Treatment: A Systematic Review and Meta-analysis. Front Med. 2016;3:71.

Uzair M, Butt G, Khurshid K, Pal S. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Our Dermatol Online. 2015;6(3):280-4.

Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns. 2014;40(4):583-8.

Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast Surg. 2007;31:468-94.

Juckett G, Hartmann-Adams H. Management of Keloids and Hypertrophic Scars. Am Fam Physician. 2009 Aug 1;80(3):253-60.

Jannati P, Aref S, Jannati AA, Jannati F, Moravvej H. Comparison of Therapeutic Response of Keloids to Cryotherapy Plus Intralesional Triamcinolone Acetonide or Verapamil Hydrochloride. J Skin Stem Cell. 2015;2(1):e29284:7-12.

Danielsen PL, Rea SM, Wood FM, Fear MW, Viola HM, Hool LC, et al. Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Controlled Trial. Acta Derm Venereol. 2016;96:774-8.

Martin MS, Collawn SS. Combination treatment of CO2 fractional laser, pulsed dye laser, and triamcinolone acetonide injection for refractory keloid scars on the upper back. J Cosmetic Laser Therap. 2013;15(3):166-70.

Sanders KW, Gage-White L, Stucker FJ. Topical mitomycin C in the prevention of keloid scar recurrence. Arch Facial Plast Surg. 2005;7:172-5.

Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician. 2009;80:253-60.

Manuskiatti W, Fitzpatrick RE. Treatment response of keloids and hypertrophic sternotomy scars. Arch Dermatol. 2002;138:1149-55.

Bilal M, Tahmeedullah, Irfanullah, Shah SA. Clinical outcome of intralesional corticosteroid versus intralesional Verapamil in the treatment of post burn Keloid scars of the head and neck region. Pak J Surg. 2013;29(4):263-8.

Downloads

Published

2018-02-26

Issue

Vol. 5 No. 3 (2018): March 2018

Section

Original Research Articles